Bioventus Inc. · NASDAQ:BVS
Bioventus — Canaccord Genuity Musculoskeletal Conference 2021
17 slides from Bioventus's conference presentation, May 20, 2021
Slide 1: Bioventus Inc.
Bioventus Inc. Canaccord Genuity Musculoskeletal Conference – May 20, 2021
Slide 2: Disclaimer
Disclaimer Forward-Looking Information This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not rela
Slide 3: Experienced Leadership Team
Experienced Leadership Team Ken Reali, Chief Executive Officer Former CEO of: Former Executive of: Greg Anglum Alessandra Pavesio John Nosenzo Tony D’Adamio SVP, Chief Financial Officer SVP, Chief Science Officer SVP, Chief Commercial Officer SVP, General Counsel Leigh Ann Stradford Katrina Church C
Slide 4: Key Investment Highlights
Key Investment Highlights 1. Broad customer reach and market access 2. Differentiated, market leading products across three verticals 3. Substantial body of peer reviewed clinical evidence 4. Robust free cash flow conversion 5. Experienced management team with a track record of value creation -4-
Slide 5: Bioventus At a Glance
Bioventus At a Glance • Bioventus offers clinically differentiated, cost efficient, and minimally Summary Financials ($MM) invasive treatments that engage and enhance the body’s natural healing process Revenue – The only complete portfolio of single, three and five injection HA viscosupplementation
Slide 6: Broad Customer and Market Access
Broad Customer and Market Access Pain Treatments and Joint Preservation Restorative Therapies Bone Graft Substitutes Sports Hand/Upper Spine Medicine Extremity Surgeons General Trauma Ortho Sponge Fiber Granules Putty Foot / Pain Ankle Neurosurgeons Total Joint Podiatric Reconstruction ~170 Independ
Slide 7: Bioventus Offers Clinically Differentiated, Cost Efficient, and Minimally Invasive Treatments
Bioventus Offers Clinically Differentiated, Cost Efficient, and Minimally Invasive Treatments That Engage and Enhance the Body’s Natural Healing Processes……. Pain Treatments and Joint Preservation Bone Graft Substitutes Restorative Therapies Granules Putty Sponge Fiber …..we believe our portfolio of
Slide 8: Fastest Growing and Now the Second Largest US HA Provider
Pain Treatments and Joint Preservation We are the Fastest Growing and Now the Second Largest US HA(1) Provider Products Market Growth Strategy Knee OA pain relief Market Expansion: Complete portfolio offering 1, 3 & 5 injection regimens ~14MM • Grow share through access and channel expansion OA
Slide 9: Pain Treatments and Joint Preservation: Development and Pipeline
Pain Treatments and Joint Preservation Pain Treatments and Joint Preservation: Development and Pipeline • ~$110MM U.S. amniotic • CartiHeal’s Agili-C technology is the only • Exclusive Collaboration Agreement • TalisMann is a next generation, less tissue market for off-the-shelf aragonite scaffold i
Slide 10: Bioventus Biologic Portfolio for Pain Treatments and Joint Preservation
Pain Treatments and Joint Preservation Bioventus Biologic Portfolio for Pain Treatments and Joint Preservation Trauma, Microtrauma, Malalignment Regenerating X Damaged Tissue Relieving Pain Injury Protecting Damaged Tissue - 10 -
Slide 11: Portfolio of Orthobiologic Products to Supplement Bone Growth
Bone Graft Substitutes Portfolio of Orthobiologic Products to Supplement Bone Growth Products Market Growth Strategy Used to supplement bone growth, Market Expansion: primarily in spine surgery ~$2.0BN U.S. • Grow share through access and channel expansion Differentiated clinical data Can be u
Slide 12: Bioventus Platform Technologies
Bone Graft Substitutes Bioventus Platform Technologies Allograft bone graft substitute with Bioactive synthetic bone graft retained growth factors to support bone with osteostimulative properties formation to activate bone cells - 12 -
Slide 13: Established Market Leader; Building Clinical Evidence to Expand Label
Restorative Therapies Established Market Leader; Building Clinical Evidence to Expand Label Products Market Growth Strategy Market Expansion: Uniquely Indicated • Expand indications for use for most nonunion ~$250MM Long fractures & select • International growth fresh fractures bone stimulation •
Slide 14: Strong Track Record of Revenue Growth ($MM)
Strong Track Record of Revenue Growth ($MM) $340 $319 $321 $275 $292 $79 $82 2016 2017 2018 2019 2020 Q1 '20 Q1 '21 70.7% 71.9% 73.6% 73.3% 72.7% 72.8% 72.8% - 14 - Gross Margin (%)
Slide 15: Strong Track Record of Improving Profitability
Strong Track Record of Improving Profitability Adjusted EBITDA $MM $79 $72 $72 70%+ Gross Margins Expanding Operating Margin Strong Cash Position ($124MM at end of Q1 ‘21) $72 >90% of EBITDA converts to free cash flow $14 $11 2018 2019 2020 Q1 '20 Q1 '21 22.6% 23.3% 22.6% 18.1% 13.5% % Net S
Slide 16: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Twelve Months Ended Three Months Ended ($, thousands) December 31, 2020 December 31, 2019 December 31, 2018 April 3, 2021 March 28, 2020 Net income 14,722 8,113 4,443 24,528 10,486 Depreciation and amortization 28,642 30,316 29,238 7,184 7,265 Income tax (benefit) expe
Slide 17: Strategy to Continue Building a Market-leading Company
Strategy to Continue Building a Market-leading Company Opportunistically grow our international markets Pursue further business development opportunities Invest in research and Grow our Restorative development Therapies portfolio through expanded indications and leveraging Further develop and synerg
Bioventus — Canaccord Genuity Musculoskeletal Conference 2021 on 6ix